GlassScriptPhysician profile
Katie J Salvati
NPI 1083005409
$6,175.54
in general payments reported to CMS, 2019-2025
34 companies · $1,495 in 2025
The $1,495 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $811 · 2022: $1,352 · 2023: $1,264 · 2024: $1,255 · 2025: $1,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,013.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $934.44 | 2021-2025 | |
| Lundbeck LLC | $905.44 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $677.38 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $490.42 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $473.66 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $354.52 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Alkermes, INC. | $339.23 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $210.19 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $210.01 | 2021-2025 | Invega Sustenna, Spravato |
| Tris Pharma INC | $207.96 | 2021-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $135.78 | 2021-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $123.63 | 2022-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $116.66 | 2024-2025 | Cobenfy |
| Biogen, INC. | $90.35 | 2024-2025 | Zurzuvae |
| Acadia Pharmaceuticals INC | $89.72 | 2022-2024 | Nuplazid |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $80.95 | 2021-2022 | |
| Corium, LLC | $73.59 | 2022-2024 | Azstarys |
| Bausch Health US, LLC | $72.05 | 2022-2023 | Aplenzin, Wellbutrin |
| Neos Therapeutics, LP | $68.75 | 2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Jazz Pharmaceuticals INC. | $63.55 | 2021-2022 | |
| Noven Therapeutics, LLC | $61.42 | 2024-2025 | Secuado, Xelstrym |
| Vanda Pharmaceuticals INC. | $58.97 | 2021-2023 | Hetlioz, Fanapt |
| Ironshore Pharmaceuticals INC. | $57.17 | 2022-2024 | |
| Itamar Medical INC | $48.60 | 2024 | Watchpatone |
| Idorsia Pharmaceuticals US INC | $46.49 | 2022-2025 | Quviviq, Quviviq |
| Collegium Pharmaceutical, INC. | $30.37 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $30.00 | 2021-2022 | |
| Almatica Pharma LLC | $29.80 | 2023-2025 | Loreev Xr |
| Indivior INC. | $20.68 | 2024 | Perseris |
| Azurity Pharmaceuticals, INC. | $19.53 | 2024 | Horizant |
| Adlon Therapeutics L.P. | $14.75 | 2021 | |
| Merck Sharp & Dohme LLC | $14.57 | 2021 | |
| Harmony Biosciences LLC | $12.67 | 2022 | |
| Alfasigma USA, INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Salvati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.